Barry Cutler, MD
Neurology · Plantation, FLNPI 1639121171
Payments from drug & device makers
Across 349 payments — averaging $3336.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$628K
- Amneal Pharmaceuticals LLC$162K
- AbbVie$130K
- Ipsen Innovation$96K
- Acadia Pharmaceuticals Inc$53K
- Lexicon Pharmaceuticals, Inc.$52K
- plus $44K from 26 others
Across 21 payments — averaging $171.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$2K
- Lexicon Pharmaceuticals, Inc.$2K
What the payments were for
- Travel & lodging$1,96943%
- Food & beverage$2,62857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 40 | $628,115 |
| Amneal Pharmaceuticals LLC | 37 | $161,764 |
| AbbVie(2 entities) | 59 | $130,213 |
| Ipsen Innovation | 99 | $95,563 |
| Acadia Pharmaceuticals Inc | 14 | $52,785 |
| Lexicon Pharmaceuticals, Inc. | 16 | $52,337 |
| Vertex | 1 | $30,371 |
| Novartis | 5 | $6,257 |
| Eisai Inc. | 21 | $2,466 |
| Pfizer | 7 | $2,143 |
| Eli Lilly | 1 | $1,000 |
| Johnson & Johnson | 6 | $189 |
| Mallinckrodt Hospital Products Inc. | 5 | $186 |
| AstraZeneca(2 entities) | 5 | $124 |
| Lundbeck LLC | 3 | $102 |
| Biogen | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $71 |
| Argenx US, Inc. | 3 | $70 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| UCB, Inc. | 2 | $41 |
| Microtransponder, Inc. | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Aucta Pharmaceuticals, Inc. | 1 | $26 |
| Life Molecular Imaging Ltd | 1 | $26 |
| SK Life Science, Inc. | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| EMD Serono, Inc. | 1 | $20 |
| Insightec,inc | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$803
How this compares
$1,164,315 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 42 | $527 |
Paid to pharmacies, not to this prescriber.
Other neurology in Plantation
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.